Glycyrrhizin

Phase 2Small molecule

MMansoura University

Glycyrrhizin is one of 28 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Mekinist

Novartis

Preclinical

3 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Ifex

BBaxter Healthcare Corporation

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Prostate Cancer

NCT06378346

Q4 2027

N/ANot yet recruiting

Medication

NCT07236567

Clinical

Trials by Indication[1]

Medication1 trial

Revascularization of Young Immature Permenant Teeth Using Different Types of Intra Canal Medication

Not yet recruiting·—·N/A·NCT07236567·45 enrolled

Randomized Controlled Trial1 trial

Molecular Analysis of Intracanal Microbes After Chemomechanical Procedure and Root Canal Medication: A Randomized Controlled Trial

Completed·MMansoura University·Phase 1·NCT06291623·20 enrolled

Prostate Cancer1 trial

GU-01: Glycyrrhizin in Prostate Cancer

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT06378346·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Glycyrrhizin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Glycyrrhizin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Glycyrrhizin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mansoura University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMansoura University

Glycyrrhizin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Medication1 trial

Randomized Controlled Trial1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News